GlassScriptPhysician profile
Marian Dam
NPI 1689049868
$6,517.73
in general payments reported to CMS, 2019-2025
38 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,306 · 2022: $1,139 · 2023: $1,534 · 2024: $1,404 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,973 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,973.26 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $629.03 | 2021-2025 | |
| Lilly USA, LLC | $574.90 | 2021-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $518.93 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Janssen Biotech, INC. | $474.61 | 2023-2025 | Tecvayli, Darzalex, Rybrevant |
| Esperion Therapeutics, INC. | $380.78 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $281.24 | 2021-2024 | |
| Amgen INC. | $260.41 | 2023-2024 | Evenity, Tepezza, Prolia |
| Mannkind Corporation | $255.38 | 2022-2023 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $238.54 | 2021-2022 | |
| Nevro Corp. | $209.59 | 2023 | Senza |
| Abbvie INC. | $198.77 | 2022-2023 | |
| Sequel Med Tech, LLC | $177.73 | 2025 | Twiist |
| Abbott Laboratories | $172.64 | 2021-2023 | Freestyle Libre 2 |
| Medtronic, INC. | $165.15 | 2021 | |
| Corcept Therapeutics | $153.01 | 2021-2023 | Korlym |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $141.32 | 2021-2025 | Recorlev |
| Kyowa Kirin, INC. | $140.00 | 2023 | |
| Renalytix Ai, INC. | $137.01 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Jazz Pharmaceuticals INC. | $136.43 | 2024 | |
| Amryt Pharma Holdings LTD | $124.98 | 2022 | |
| Alexion Pharmaceuticals, INC. | $124.95 | 2024 | |
| Dexcom, INC. | $124.33 | 2021-2023 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $121.83 | 2025 | Yorvipath |
| Madrigal Pharmaceuticals | $109.67 | 2024 | Rezdiffra |
| Kite Pharma, INC. | $100.00 | 2024 | Yescarta |
| Incyte Corporation | $99.38 | 2025 | Niktimvo |
| Recordati_rare_diseases_inc. | $96.56 | 2022-2025 | Isturisa |
| Zealand Pharma US, INC. | $95.80 | 2021 | |
| Legend Biotech USA INC. | $78.49 | 2024-2025 | Carvykti |
| Eusa Pharma (US) LLC | $42.85 | 2022 | |
| Sage Therapeutics, LLC | $35.38 | 2025 | Zurzuvae |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.75 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $20.50 | 2021 | |
| Amneal Pharmaceuticals LLC | $19.53 | 2023 | Unithroid |
| Radius Health, INC. | $14.79 | 2021 | |
| Globus Medical, INC. | $13.49 | 2025 | Senza |
| Ibsa Pharma INC. | $13.28 | 2022 | |
| Amarin Pharma, INC. | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marian Dam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.